Samjin Pharmaceutical said on the 13th that it signed a strategic memorandum of understanding (MOU) with Ewha Womans University Seoul Hospital for research on central nervous system (CNS) disease therapies.
Under the agreement, the two institutions will launch joint research on therapies for central nervous system diseases, including migraines.
The two institutions will divide roles to carry out the research. Samjin Pharmaceutical will take charge of the early stages of new drug development, including preclinical evaluations such as antibody discovery and engineering, lead optimization, and cell and animal studies. Ewha Womans University Seoul Hospital will support understanding of diseases and pathophysiology based on its clinical expertise and patient-based research experience and provide principle verification advice from the perspective of clinical efficacy.
Professor Song Tae-jin, who took office as head of the Institute of Medical Science at Ewha Womans University in Mar., will participate in this study. Song, a specialist in the field of migraines, is expected to provide clinical advice and principle verification.
The two institutions will also consider participating in national projects and industry-academia-research collaboration programs going forward. Intellectual property (IP) ownership, scope of roles, expense sharing and commercialization structure arising during the joint research will be set by separate contracts.
Lee Su-min, head of the research center at Samjin Pharmaceutical, said, "We will accelerate the development of therapies for central nervous system diseases by combining Ewha Womans University Seoul Hospital's clinical expertise with our antibody research capabilities."
In particular, Professor Song Tae-jin, who took office as head of the Institute of Medical Science at Ewha Womans University in Mar., is a leading specialist in the field of migraines and is expected to play a key role in clinical advice and validation of disease mechanisms in this joint study.
In addition, Samjin Pharmaceutical and Ewha Womans University Seoul Hospital plan to actively consider participating in joint research through national projects and industry-academia-research cooperation programs under this agreement, and agreed to detail, through future separate agreements and contracts, matters arising during the joint research, including ▲ intellectual property (IP) ownership ▲ scope of roles ▲ expense sharing and commercialization structure.
Lee Su-min, head of the research center at Samjin Pharmaceutical, said, "We will accelerate the development of therapies for central nervous system diseases by combining Ewha Womans University Seoul Hospital's clinical expertise with our antibody research capabilities."